The goal of this observational study is to develop an integrated clinical-molecular risk stratification to identifypatients who are at high risk of recurrence and who would benefit from adjuvant chemotherapy in patients with recectable colorectal liver metastases. The main question it aims to answer is: can the integration of multi-dimensional data-including ctDNA, driver gene profiles, and clinical factors-accurately identify postoperative patients at high risk of recurrence and guide personalized adjuvant therapy strategies?
Aged 18 to 75 years, inclusive (male or female).
Pathologically and radiologically confirmed colorectal cancer with liver metastases.
Must have undergone complete (R0) surgical resection of both the primary colorectal tumor and all liver metastases.
Have adequate organ function and no contraindications to potential adjuvant therapies (surgery, chemotherapy, radiotherapy, immunotherapy).
Pregnancy or breast-feeding women
History of other malignancies within 5 years (except cured skin cancer and cervicalcancer in situ)
History of uncontrolled epilepsy, central nervous system disease, or psychiatricdisorders
Clinically serious heart disease, such as symptomatic coronary artery disease, NewYork Heart Association (NYHA) class II or worse congestive heart failure or severearrhythmia requiring pharmacologic intervention, or history of myocardial infarctionwithin the last 12 months